SCHEMBL4539730

SCHEMBL4539730

CC(CO)N(C(=O)OC(C)(C)C)c1cccc(Cl)n1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.34
KMT2A Q03164 1/20 0.34
ALDH1A1 P00352 3/20 0.33
TRPA1 O75762 1/20 0.33
GAA P10253 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
GRM2 Q14416 1/20 0.31
POLB P06746 1/20 0.31
MAPK1 P28482 1/20 0.31
ATM Q13315 1/20 0.31
USP30 Q70CQ3 1/20 0.31
LCK P06239 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
CYP2B6 P20813 1/20 0.31
NQO2 P16083 1/20 0.31
SCN9A Q15858 1/20 0.31
SLC7A5 Q01650 1/20 0.30
CYP3A4 P08684 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4540392 0.86 SSTR4 (0.34) GRM2USP30SLC7A5
SCHEMBL1642844 0.76 CYP2B6 (0.41) ALDH1A1GAASMN1; SMN2CYP2B6
SCHEMBL1134230 0.74 SMN1; SMN2 (0.43) LMNAKMT2AALDH1A1SMN1; SMN2ATM
SCHEMBL3288030 0.74 SMN1; SMN2 (0.43) LMNAKMT2AALDH1A1SMN1; SMN2ATM
SCHEMBL7442872 0.73 BACE1 (0.39) KMT2AALDH1A1L3MBTL1NQO2
SCHEMBL15240728 0.72 GBA1 (0.39) KMT2AALDH1A1SMN1; SMN2USP30
SCHEMBL10261793 0.72 USP30 (0.39) USP30
SCHEMBL7277620 0.72 USP30 (0.37) USP30
SCHEMBL7277631 0.72 USP30 (0.37) USP30
SCHEMBL8269446 0.71 USP30 (0.38) USP30SLC7A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49735-E1 Oxazolidinones as modulators of MGLUR5 BRISTOL-MYERS SQUIBB COMPANY (US) 2023-11-28 US disclosed
EP-2638022-B1 OXAZOLIDINONES AS MODULATORS OF MGLUR5 BRISTOL MYERS SQUIBB CO (US) 2014-12-24 EP disclosed
EP-2638022-A1 OXAZOLIDINONES AS MODULATORS OF MGLUR5 Bristol-Myers Squibb Company (US) 2013-09-18 EP disclosed
US-20120283264-A1 Oxazolidinones as Modulators of MGLUR5 BRISTOL-MYERS SQUIBB COMPANY 2012-11-08 US disclosed
WO-2012064603-A1 OXAZOLIDINONES AS MODULATORS OF MGLUR5 BRISTOL-MYERS SQUIBB COMPANY (US) 2012-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283264-A1 Oxazolidinones as Modulators of MGLUR5 GRM5, GRIK5, GRM1 LMNA 4607/4885KMT2A 3071/4885ALDH1A1 3633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.